Dec 22 (Reuters) - British drugmaker AstraZeneca Plc
told Reuters on Tuesday that its COVID-19 vaccine should be
effective against the new coronavirus variant, adding that
studies were under way to fully probe the impact of the
mutation.
"AZD1222 (AstraZeneca's vaccine candidate) contains the
genetic material of the SARS-CoV-2 virus spike protein, and the
changes to the genetic code seen in this new viral strain do not
appear to change the structure of the spike protein," an
AstraZeneca spokesperson said in an email.
(Reporting by Kanishka Singh in Bengaluru; Editing by Leslie
Adler)
Astrazeneca (AZN)
